25iP-NBOMe

25iP-NBOMe, also known as 2C-iP-NBOMe or NBOMe-2C-iP, is a derivative of the phenethylamine hallucinogen 2C-iP, which has been encountered as a novel designer drug.

Pharmacology

The interactions of 25iP-NBOMe with the μ-opioid receptor have been described.

History

25iP-NBOMe was first described in the scientific literature by at least 2014, when it was encountered as a novel designer drug.

Society and culture

Legal status

Canada

25iP-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.